TP-05: An investigational therapeutic for the prevention of Lyme disease
TP-05 is an oral, systemic formulation of lotilaner in development for the prevention of Lyme disease.1
Currently, there is no FDA-approved pharmacological option for preventing Lyme disease.1
Believed to be the only non-vaccine, drug-based, preventive therapeutic in development that targets and kills infected tick vectors before they can transmit the Borrelia bacteria that causes Lyme disease
An oral formulation intended to rapidly provide systemic blood levels of lotilaner, a well-characterized anti-parasitic agent, for on-demand protection
Currently being evaluated in the Phase 1 Callisto trial
1. Tarsus Pharmaceuticals, Inc. initiates phase 1 Callisto trial of TP-05, a novel, oral, non-vaccine therapeutic for the prevention of Lyme disease. Tarsus Pharmaceuticals, Inc. Press release. June 16, 2021.
Learn more about our efforts to prevent Lyme disease.
Please reach out to us using the form below.
Thank you for getting in touch! Someone from our team will respond shortly.